Effects of the repeated administration of adenosine and heparin on myocardial perfusion in patients with chronic stable angina pectoris.
The mechanism by which ischemia stimulates angiogenesis is unknown. Adenosine is released during myocardial ischemia and may be a mediator of this process. Experimental data suggest that heparin may enhance this effect. The purpose of this open-labeled, placebo-controlled trial was to determine whether repeated intravenous administration of adenosine and heparin could mimic physiologic angiogenesis and reduce the amount of exercise-induced myocardial ischemia in patients with coronary artery disease. Subjects with chronic stable angina refractory to conventional medical therapy and not suitable for revascularization received either adenosine (140 microg/kg/min for 6 minutes) and heparin (10,000 U bolus), (n = 14), or placebo, (n = 7) daily for 10 days. All patients underwent baseline and follow-up exercise testing with thallium-201 single-photon emission computed tomography myocardial perfusion imaging. A semiquantitative assessment of the extent and severity of the perfusion abnormalities was calculated by 2 blinded investigators. There was no significant change in exercise duration or in the peak heart rate systolic blood pressure product associated with adenosine and heparin compared with placebo treatment. There was, however, a 9% reduction in the extent (60.6 +/- 4.0 vs 54.9 +/- 4.1, p = 0.03) and a 14% improvement in severity (41.5 +/- 3.2 vs 35.7 +/- 2.9, p = 0.01) of the myocardial perfusion abnormalities seen in patients who received adenosine and heparin compared with placebo. Thus, in this pilot study, repeated administration of adenosine and heparin reduced the amount of exercise-induced ischemia in patients with chronic stable angina refractory to conventional treatment.
Barron
H V
HV
Department of Medicine Cardiology, University of California, San Francisco, USA.
Sciammarella
M G
MG
Lenihan
K
K
Michaels
A D
AD
Botvinick
E H
EH
D000241:Adenosine / Q000627:therapeutic use*; D000787:Angina Pectoris / Q000150:complications* / Q000188:drug therapy*; D000925:Anticoagulants / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002908:Chronic Disease; D003097:Collateral Circulation / Q000187:drug effects*; D004359:Drug Therapy, Combination; D005080:Exercise Test; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000145:classification / Q000175:diagnosis / Q000209:etiology* / Q000503:physiopathology; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D010865:Pilot Projects; D012720:Severity of Illness Index; D016037:Single-Blind Method; D013599:Systole; D013794:Thallium Radioisotopes; D015899:Tomography, Emission-Computed, Single-Photon; D014665:Vasodilator Agents / Q000627:therapeutic use*
D000925:Anticoagulants; D013794:Thallium Radioisotopes; D014665:Vasodilator Agents; D006493:Heparin; D000241:Adenosine